company background image
3692

Hansoh Pharmaceutical Group SEHK:3692 Stock Report

Last Price

HK$15.04

Market Cap

HK$90.5b

7D

-5.5%

1Y

-41.9%

Updated

17 Aug, 2022

Data

Company Financials +
3692 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance2/6
Financial Health5/6
Dividends0/6

3692 Stock Overview

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China.

Hansoh Pharmaceutical Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hansoh Pharmaceutical Group
Historical stock prices
Current Share PriceHK$15.04
52 Week HighHK$26.20
52 Week LowHK$12.00
Beta0.30
1 Month Change-3.09%
3 Month Change11.91%
1 Year Change-41.93%
3 Year Change-36.67%
5 Year Changen/a
Change since IPO-22.87%

Recent News & Updates

Jun 09
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

In this article we are going to estimate the intrinsic value of Hansoh Pharmaceutical Group Company Limited ( HKG:3692...

Shareholder Returns

3692HK PharmaceuticalsHK Market
7D-5.5%-2.8%-0.5%
1Y-41.9%-35.7%-20.6%

Return vs Industry: 3692 underperformed the Hong Kong Pharmaceuticals industry which returned -35.7% over the past year.

Return vs Market: 3692 underperformed the Hong Kong Market which returned -20.6% over the past year.

Price Volatility

Is 3692's price volatile compared to industry and market?
3692 volatility
3692 Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.6%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 3692 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 3692's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199512,150Huijuan Zhonghttps://www.hspharm.com

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs.

Hansoh Pharmaceutical Group Fundamentals Summary

How do Hansoh Pharmaceutical Group's earnings and revenue compare to its market cap?
3692 fundamental statistics
Market CapHK$90.49b
Earnings (TTM)HK$3.13b
Revenue (TTM)HK$11.48b

28.4x

P/E Ratio

7.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
3692 income statement (TTM)
RevenueCN¥9.94b
Cost of RevenueCN¥870.39m
Gross ProfitCN¥9.06b
Other ExpensesCN¥6.35b
EarningsCN¥2.71b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.46
Gross Margin91.24%
Net Profit Margin27.31%
Debt/Equity Ratio18.7%

How did 3692 perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

16%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 3692 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3692?

Other financial metrics that can be useful for relative valuation.

3692 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.3x
Enterprise Value/EBITDA19.7x
PEG Ratio1.9x

Price to Earnings Ratio vs Peers

How does 3692's PE Ratio compare to its peers?

3692 PE Ratio vs Peers
The above table shows the PE ratio for 3692 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average8.7x
1177 Sino Biopharmaceutical
4.7x-36.4%HK$80.1b
1093 CSPC Pharmaceutical Group
15.1x11.3%HK$96.5b
874 Guangzhou Baiyunshan Pharmaceutical Holdings
7x0.8%HK$49.7b
3320 China Resources Pharmaceutical Group
7.9x9.7%HK$29.7b
3692 Hansoh Pharmaceutical Group
28.4x15.1%HK$89.1b

Price-To-Earnings vs Peers: 3692 is expensive based on its Price-To-Earnings Ratio (28.4x) compared to the peer average (8.7x).


Price to Earnings Ratio vs Industry

How does 3692's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 3692 is expensive based on its Price-To-Earnings Ratio (28.4x) compared to the Hong Kong Pharmaceuticals industry average (7.8x)


Price to Earnings Ratio vs Fair Ratio

What is 3692's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3692 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.4x
Fair PE Ratio17.3x

Price-To-Earnings vs Fair Ratio: 3692 is expensive based on its Price-To-Earnings Ratio (28.4x) compared to the estimated Fair Price-To-Earnings Ratio (17.2x).


Share Price vs Fair Value

What is the Fair Price of 3692 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3692 (HK$15.04) is trading below our estimate of fair value (HK$28.63)

Significantly Below Fair Value: 3692 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Hansoh Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3692's forecast earnings growth (15.1% per year) is above the savings rate (1.6%).

Earnings vs Market: 3692's earnings (15.1% per year) are forecast to grow slower than the Hong Kong market (16.7% per year).

High Growth Earnings: 3692's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3692's revenue (11.7% per year) is forecast to grow faster than the Hong Kong market (9.9% per year).

High Growth Revenue: 3692's revenue (11.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 3692's Return on Equity is forecast to be low in 3 years time (15.1%).


Discover growth companies

Past Performance

How has Hansoh Pharmaceutical Group performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


11.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 3692 has high quality earnings.

Growing Profit Margin: 3692's current net profit margins (27.3%) are lower than last year (29.6%).


Past Earnings Growth Analysis

Earnings Trend: 3692's earnings have grown by 11.7% per year over the past 5 years.

Accelerating Growth: 3692's earnings growth over the past year (5.6%) is below its 5-year average (11.7% per year).

Earnings vs Industry: 3692 earnings growth over the past year (5.6%) underperformed the Pharmaceuticals industry 15.2%.


Return on Equity

High ROE: 3692's Return on Equity (13.5%) is considered low.


Discover strong past performing companies

Financial Health

How is Hansoh Pharmaceutical Group's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 3692's short term assets (CN¥23.2B) exceed its short term liabilities (CN¥3.0B).

Long Term Liabilities: 3692's short term assets (CN¥23.2B) exceed its long term liabilities (CN¥4.1B).


Debt to Equity History and Analysis

Debt Level: 3692 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 3692's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 3692's debt is well covered by operating cash flow (68.9%).

Interest Coverage: 3692 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Hansoh Pharmaceutical Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.58%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 3692's dividend (0.58%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.84%).

High Dividend: 3692's dividend (0.58%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.33%).


Stability and Growth of Payments

Stable Dividend: 3692 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.

Growing Dividend: 3692 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: 3692 is not paying a notable dividend for the Hong Kong market.


Cash Payout to Shareholders

Cash Flow Coverage: 3692 is not paying a notable dividend for the Hong Kong market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.7yrs

Average management tenure


CEO

Huijuan Zhong (61 yo)

6.67yrs

Tenure

Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...


Leadership Team

Experienced Management: 3692's management team is seasoned and experienced (6.7 years average tenure).


Board Members

Experienced Board: 3692's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hansoh Pharmaceutical Group Company Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Hansoh Pharmaceutical Group Company Limited
  • Ticker: 3692
  • Exchange: SEHK
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$90.494b
  • Shares outstanding: 5.92b
  • Website: https://www.hspharm.com

Number of Employees


Location

  • Hansoh Pharmaceutical Group Company Limited
  • No.45 Huanghe Road
  • Economic & Technical Development Zone
  • Lianyungang
  • Jiangsu Province
  • 222069
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/17 00:00
End of Day Share Price2022/08/17 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.